BioMedNewsBreaks Archive - Page 11 of 246

ThursdaySep 25, 2025 9:33 am

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Presents Positive REPAIR-MS Results at ECTRIMS 2025

Clene (NASDAQ: CLNN) announced presentation of combined REPAIR-MS trial results at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis in Barcelona, showing CNM-Au8 significantly improved brain NAD+/NADH ratios, a key marker of energetic capacity, across relapsing and non-active progressive MS patients. Treatment also produced significant changes in brain NAD+ and NADH fractions, with correlations between baseline brain energy metabolism and disability, cognition, and motor function. CNM-Au8 was safe and well tolerated, reinforcing its potential to slow disease progression by addressing bioenergetic failure in MS. To view the full press release, visit https://ibn.fm/uuEAj About Clene Inc.…

ThursdaySep 25, 2025 9:30 am

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) to Present at MicroCap Rodeo Conference

Nutriband (NASDAQ: NTRB) announced it will participate in the MicroCap Rodeo Conference in New York City on Sept. 25, 2025. Company Chairman Serguei Melnik will present at 10 a.m., discussing operational highlights, growth initiatives, and the strategic direction for its AVERSA platform technology. The presentation will be webcast live, with registration available for interested parties. To view the full press release, visit https://ibn.fm/7JiVo About Nutriband Inc. We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA(TM) abuse-deterrent technology. AVERSA(TM) technology can be incorporated…

ThursdaySep 25, 2025 9:10 am

BioMedNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Highlights AI Role in Breast Imaging With New Feature Article

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) announced the publication of a feature article on BreastCT.com titled “AI Is Reshaping Breast Imaging, and IzoView Was Built for What Comes Next.” The piece underscores the limitations of legacy systems and details how the Company’s flagship IzoView Breast CT Imaging System was purpose-built for AI-driven imaging. Key points include global validation of AI’s role in improving cancer detection, IzoView’s proprietary 3D hardware and 10-second compression-free scans, and its positioning as a scalable, protected platform with a $500,000 target price designed to set a new standard in breast cancer screening. To view the…

WednesdaySep 24, 2025 3:50 pm

BioMedNewsBreaks — Solving the Value-Based Care Puzzle: Adageis Brings Clarity with AI

Adageis, a growing healthcare technology company with a patented AI-driven platform, is positioning its software as a practical solution for providers seeking clarity in the transition from fee-for-service to value-based care. “By focusing on simplicity, contract visibility, and measurable financial outcomes, the firm aims to address one of the most pressing challenges in U.S. healthcare: how to reward high-quality care with appropriate compensation,” reads a recent article. “Adageis’ combination of AI, contract visibility, and financial monitoring places it at the intersection of healthcare technology and financial analytics. The company’s strategy, emphasizing simplicity, visibility, and measurable financial gain, is designed to…

WednesdaySep 24, 2025 11:14 am

BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives FDA Approval of Suitability Petition for Preservative-Free Ketamine Product

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration has granted its Suitability Petition for KETAFREE(TM), a planned single-patient, preservative-free ketamine product. Unlike current ketamine offerings in multi-dose vials containing the toxic preservative Benzethonium Chloride, KETAFREE(TM) is designed to eliminate such additives. The approval enables immediate re-filing of the Company’s Abbreviated New Drug Application. NRx noted the product supports federal priorities of re-shoring sterile drug manufacturing and removing harmful preservatives, with the ketamine market estimated at $750 million. The Company is also advancing NRX-100, a non-generic ketamine formulation under development for suicidal depression…

WednesdaySep 24, 2025 9:40 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Joint Venture Sapu Nano Receives Approval to Begin Phase 1 Trial of Injectable Everolimus for Breast Cancer

Oncotelic Therapeutics (OTCQB: OTLC) announced that its joint venture through GMP Biotechnology Limited, Sapu Nano, has received approval from Australia’s Human Research Ethics Committee to begin enrolling patients in a Phase 1 human clinical trial of Sapu003, an injectable form of Everolimus for breast cancer. Everolimus, marketed as Afinitor(R), is FDA-approved in oral form but has limited absorption of about 10%. Using Sapu Nano’s Deciparticle(TM) technology, Sapu003 is delivered intravenously, allowing full drug absorption into the bloodstream. Preclinical data suggest this approach could improve efficacy over the oral version. The trial will determine optimal dosing for future studies, including a…

TuesdaySep 23, 2025 12:42 pm

BioMedNewsBreaks — Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Integrates Radiation Dose Personalization into IzoView Breast CT System

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company focused on advanced breast cancer imaging technologies, announced the integration of a patent-pending radiation dose personalization feature into its IzoView Breast CT Imaging System. The innovation uses a radiation-free optical pre-scan and proprietary software to calculate customized dosing for each patient’s breast size, streamlining exam setup and improving comfort. Developed using models from UC Davis Medical Center, the system positions IzoView as the first breast CT to offer real-time personalized dosing. With the global breast imaging market projected to grow to $8.69 billion by 2030, Izotropic is advancing IzoView…

TuesdaySep 23, 2025 11:35 am

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL, NXPLW) Advances Development of ClearMetrX 4.0 With AI-Enhanced Healthcare Analytics

NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company, announced its ClearMetrx subsidiary has entered late-stage development of ClearMetrX 4.0, the next generation of its proprietary healthcare data analytics and reporting software. Scheduled for internal rollout in Q4 2025 and commercialization in the first half of 2026, ClearMetrX 4.0 integrates AI-powered capabilities including revenue forecasting, predictive inventory management, anomaly detection, fraud prevention, audit support, and scenario modeling. The cloud-based platform is already in use across the Company’s pharmacies and client network, streamlining analytics for physicians, MSOs, 340B entities, and pharmacies. NextPlat said the upgrade reflects its commitment to…

TuesdaySep 23, 2025 11:05 am

BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Appoints Tomas J. Philipson, PhD as Strategic Advisor

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases, announced the appointment of Tomas J. Philipson, PhD as a Strategic Advisor. Dr. Philipson, an expert in U.S. economic and healthcare policy with extensive academic, business, and government experience, previously served as acting chairman of the White House Council of Economic Advisers and has advised FDA, CMS, and major healthcare initiatives. He currently serves as Managing Partner of MEDA Ventures and on several corporate boards. Soligenix CEO Christopher J. Schaber, PhD, said Philipson’s expertise and relationships will be instrumental as the company advances…

TuesdaySep 23, 2025 10:18 am

BioMedNewsBreaks — Fifty 1 Labs, Inc. (OTC: FITY) Engages PCAOB Auditor to Support Planned OTCQB Uplist

Fifty 1 Labs (OTC: FITY), a Nevada-based holding company focused on AI-driven drug repurposing and functional medicine, announced it has signed a letter of engagement with a Public Company Accounting Oversight Board registered auditing firm to conduct audits of its 2024 and 2025 financial statements. The audits mark a key step in the company’s plan to uplist to the OTCQB Venture Market, which requires strict reporting and governance standards. CEO Paul Arora said the engagement underscores Fifty 1 Labs’ commitment to transparency and corporate governance, while laying the groundwork to strengthen investor confidence as it advances biotech and wellness initiatives.…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Presents Positive REPAIR-MS Results at ECTRIMS 2025

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) to Present at MicroCap Rodeo Conference

BioMedNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Highlights AI Role in Breast Imaging With New Feature Article

BioMedNewsBreaks — Solving the Value-Based Care Puzzle: Adageis Brings Clarity with AI

BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives FDA Approval of Suitability Petition for Preservative-Free Ketamine Product

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Joint Venture Sapu Nano Receives Approval to Begin Phase 1 Trial of Injectable Everolimus for Breast Cancer

BioMedNewsBreaks — Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Integrates Radiation Dose Personalization into IzoView Breast CT System

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL, NXPLW) Advances Development of ClearMetrX 4.0 With AI-Enhanced Healthcare Analytics

BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Appoints Tomas J. Philipson, PhD as Strategic Advisor

BioMedNewsBreaks — Fifty 1 Labs, Inc. (OTC: FITY) Engages PCAOB Auditor to Support Planned OTCQB Uplist

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search